Vertex Pharmaceuticals Incorporated 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-06-05 4:10 pm Sale |
2023-06-01 | 13D | Kymera Therapeutics, Inc. KYMR |
VERTEX PHARMACEUTICALS INC VRTX |
0 0.000% |
-3,151,121 (Position Closed) |
Filing |
| 2020-09-03 4:12 pm Purchase |
2020-08-25 | 13D | Kymera Therapeutics, Inc. KYMR |
VERTEX PHARMACEUTICALS INC VRTX |
3,151,121 7.100% |
3,151,121 (New Position) |
Filing |